Table 3.

Adverse event distribution during the double-blind period

Adverse EventsPlacebo(n = 9)Satavaptan
25 mg (n = 14)50 mg (n = 12)
Urinary tract infection011
Vomiting010
Pruritus010
Stomatitis100
Vasculitisa100
Cryoglobulinemia100
  • a Serious adverse event.